Free Trial
→ The Midwestern Disruptor Big Pharma Doesn’t Want You to Know About (From Compounding Quality) (Ad)tc pixel Free SBTX Stock Alerts

SkinBioTherapeutics (SBTX) Competitors

SkinBioTherapeutics logo
GBX 5.95 -0.05 (-0.83%)
As of 06:24 AM Eastern
Compare

SBTX vs. POLB, ETX, HEMO, HVO, and C4XD

Should you buy SkinBioTherapeutics stock or one of its competitors? SkinBioTherapeutics's main competitors and comparable companies include Poolbeg Pharma (POLB), e-therapeutics (ETX), Hemogenyx Pharmaceuticals (HEMO), hVIVO (HVO), and C4X Discovery (C4XD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SkinBioTherapeutics compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Poolbeg Pharma has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -71.28% -21.33%
SkinBioTherapeutics -8.73%-5.25%-61.18%

SkinBioTherapeutics has higher revenue and earnings than Poolbeg Pharma. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.79N/A
SkinBioTherapeutics£5.23M2.73-£3.71M-£0.16N/A

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 3.5% of SkinBioTherapeutics shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Poolbeg Pharma has a beta of 1.828, indicating that its share price is 83% more volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.104, indicating that its share price is 90% less volatile than the broader market.

In the previous week, Poolbeg Pharma had 2 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 2 mentions for Poolbeg Pharma and 0 mentions for SkinBioTherapeutics. Poolbeg Pharma's average media sentiment score of 0.53 beat SkinBioTherapeutics' score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Poolbeg Pharma Positive
SkinBioTherapeutics Neutral

Summary

Poolbeg Pharma beats SkinBioTherapeutics on 7 of the 12 factors compared between the two stocks.

How does SkinBioTherapeutics compare to e-therapeutics?

e-therapeutics (LON:ETX) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

SkinBioTherapeutics has higher revenue and earnings than e-therapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
e-therapeutics£295K0.00-£10.06M-£0.02N/A
SkinBioTherapeutics£5.23M2.73-£3.71M-£0.16N/A

e-therapeutics has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat e-therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
e-therapeuticsN/A -38.75% -29.10%
SkinBioTherapeutics -8.73%-5.25%-61.18%

26.5% of e-therapeutics shares are held by institutional investors. Comparatively, 3.5% of SkinBioTherapeutics shares are held by institutional investors. 59.4% of e-therapeutics shares are held by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, e-therapeutics' average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
e-therapeutics Neutral
SkinBioTherapeutics Neutral

e-therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.104, indicating that its stock price is 90% less volatile than the broader market.

Summary

e-therapeutics beats SkinBioTherapeutics on 6 of the 10 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Hemogenyx Pharmaceuticals?

SkinBioTherapeutics (LON:SBTX) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M2.73-£3.71M-£0.16N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£130.80N/A

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Hemogenyx Pharmaceuticals N/A -409.57%-37.79%

SkinBioTherapeutics has a beta of 0.104, meaning that its share price is 90% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.487, meaning that its share price is 49% more volatile than the broader market.

3.5% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by insiders. Comparatively, 0.9% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

SkinBioTherapeutics and Hemogenyx Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does SkinBioTherapeutics compare to hVIVO?

hVIVO (LON:HVO) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

hVIVO has a beta of 1.694, indicating that its stock price is 69% more volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.104, indicating that its stock price is 90% less volatile than the broader market.

hVIVO presently has a consensus target price of GBX 16.33, suggesting a potential upside of 181.12%. Given hVIVO's stronger consensus rating and higher possible upside, research analysts clearly believe hVIVO is more favorable than SkinBioTherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
SkinBioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

SkinBioTherapeutics has a net margin of -8.73% compared to hVIVO's net margin of -31.76%. SkinBioTherapeutics' return on equity of -5.25% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-31.76% -35.13% 11.97%
SkinBioTherapeutics -8.73%-5.25%-61.18%

12.7% of hVIVO shares are owned by institutional investors. Comparatively, 3.5% of SkinBioTherapeutics shares are owned by institutional investors. 4.9% of hVIVO shares are owned by company insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

hVIVO has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£38.85M1.03£17.84M-£1.78N/A
SkinBioTherapeutics£5.23M2.73-£3.71M-£0.16N/A

In the previous week, hVIVO had 6 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 6 mentions for hVIVO and 0 mentions for SkinBioTherapeutics. hVIVO's average media sentiment score of 0.47 beat SkinBioTherapeutics' score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company Overall Sentiment
hVIVO Neutral
SkinBioTherapeutics Neutral

Summary

hVIVO beats SkinBioTherapeutics on 12 of the 16 factors compared between the two stocks.

How does SkinBioTherapeutics compare to C4X Discovery?

C4X Discovery (LON:C4XD) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

C4X Discovery has a net margin of 42.81% compared to SkinBioTherapeutics' net margin of -8.73%. C4X Discovery's return on equity of 55.38% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
SkinBioTherapeutics -8.73%-5.25%-61.18%

52.1% of C4X Discovery shares are owned by institutional investors. Comparatively, 3.5% of SkinBioTherapeutics shares are owned by institutional investors. 27.1% of C4X Discovery shares are owned by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

C4X Discovery has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
SkinBioTherapeutics£5.23M2.73-£3.71M-£0.16N/A

In the previous week, C4X Discovery's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
SkinBioTherapeutics Neutral

C4X Discovery has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.104, meaning that its share price is 90% less volatile than the broader market.

Summary

C4X Discovery beats SkinBioTherapeutics on 10 of the 10 factors compared between the two stocks.

Get SkinBioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

Export
MetricSkinBioTherapeuticsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£15.42M£3.88B£7.25B£2.80B
Dividend YieldN/A3.65%2.52%6.26%
P/E Ratio-37.1913.03275.44366.78
Price / Sales2.951,148.01562.0588,865.26
Price / Cash9.00118.5077.1627.85
Price / Book3.5416.7510.647.07
Net Income-£3.71M-£22.65M£3.49B£5.89B
7 Day Performance11.30%-4.89%-3.21%0.25%
1 Month Performance-37.37%-12.84%-7.65%-0.03%
1 Year Performance-57.51%7.43%2.92%22.90%

SkinBioTherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
SkinBioTherapeutics
N/AGBX 5.95
-0.8%		N/A-61.8%£15.42M£5.23MN/A11
POLB
Poolbeg Pharma
N/AGBX 6.90
flat		N/A+80.5%£52.68MN/AN/A12
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 735
+14.8%		N/A-31.8%£50.69MN/AN/A14
HVO
hVIVO
1.8164 of 5 stars		GBX 6
-2.4%		GBX 15
+150.0%		-25.5%£41.30M£38.85MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SBTX) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
The AI Infrastructure Play Kevin O'Leary Is Backing
Kevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...
The Tomorrow Investor | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
AI Microcap Teams With Gentex on Next-Gen Military Helmets
Morgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion...
Capital Trends | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
Trump's crypto bank just got approved
Last month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...
Crypto 101 Media | Sponsoredtc pixel